KBI-436

N/A

Report date: 2025/06/11 14:31:00

Base Information

Drug NameKBI-436

Drug Alias NameKBI-436

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionAnti-PD-1Dopamine D2 receptor antagonists

TargetsProgrammed cell death protein 1Dopamine D2 receptor

Therapy Area/IndicationsSolid tumoursSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesKisoji Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKisoji Biotechnology Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A